From Morningstar this morningShares look overvalued
Shares are overvalued with earnings growth rates from recent years unlikely to be repeated.
Our AUD 235 fair value estimate factors in a revenue compound annual growth rate of 8% to fiscal 2029 and operating margins expanding to 26% by fiscal 2029, resulting in adjusted earnings per share growth of 11%.
In the core implant segment, we assume units sold per year grow at 8% and revenue growth of 8%, assuming a flat US dollar/Australian dollar exchange rate of 0.65.
Less than 10% of Cochlear’s revenue is earned in Australian dollars and approximately half of the costs are in Australian dollars. Therefore, a weakening Australian dollar is beneficial to Cochlear’s bottom line.
Ann: Cochlear provides update to FY25 earnings guidance, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$312.83 |
Change
-1.180(0.38%) |
Mkt cap ! $20.45B | |||
| Open | High | Low | Value | Volume |
| $314.04 | $316.34 | $312.83 | $32.53M | 103.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $312.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $314.51 | 72 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| COH (ASX) Chart |